SCHEMBL5068779

SCHEMBL5068779

O=C(O)c1ccc2c(ccn2COCc2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 2/20 0.44
PPARG P37231 3/20 0.43
BCL2 P10415 3/20 0.43
MCL1 Q07820 3/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
NR4A2 P43354 2/20 0.43
PLG P00747 1/20 0.42
PLAU P00749 1/20 0.42
NR4A1 P22736 1/20 0.42
NR4A3 Q92570 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
F2 P00734 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
SRD5A2 P31213 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30888879 0.82 PLAU (0.57) PPARGPLGPLAUHDAC11HDAC8
SCHEMBL15971036 0.82 PLAU (0.57) PPARGPLGPLAUHDAC11HDAC8
SCHEMBL4592638 0.81 PLA2G4A (0.54) PLA2G4APPARGBCL2MCL1PPARD
SCHEMBL28586559 0.80 RORC (0.50) PLA2G4APPARGBCL2MCL1PPARD
SCHEMBL5071873 0.79 PLA2G4A (0.51) PLA2G4APPARGMCL1PPARDPPARA
SCHEMBL3596090 0.75 LMNA (0.51) PLGPLAUKMT2AHDAC11HDAC8
SCHEMBL5068315 0.75 TUBB4A (0.57) PLA2G4APPARGPPARDPPARAPLG
SCHEMBL5387474 0.74 TUBB4A (0.59) PLA2G4APPARGPLGPLAUKMT2A
SCHEMBL2983210 0.74 PLA2G4A (0.48) PLA2G4APPARGPPARDPPARAPLG
SCHEMBL28607801 0.74 KMT2A (0.60) PLA2G4APPARGPPARDPPARAPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595866-B1 Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome SANWA KAGAKU KENKYUSHO CO (JP) 2016-06-08 EP disclosed
US-7345180-B2 Compound inhibiting dipeptidyl peptidase IV SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2008-03-18 US disclosed
US-20060229286-A1 Compound inhibiting dipeptidyl peptidase IV SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2006-10-12 US disclosed
CN-1745063-A Compound inhibiting dipeptidyl peptidase iv SANWA KAGAKU KENKYUSHO CO (JP) 2006-03-08 CN disclosed
EP-1595866-A1 COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV Sanwa Kagaku Kenkyusho Co., Ltd. (JP) 2005-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229286-A1 Compound inhibiting dipeptidyl peptidase IV DPP4, DPP3, DPP7 PLA2G4A 4463/4885PPARG 3132/4885BCL2 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.